Jacob Johnson
Stock Analyst at Stephens & Co.
(3.57)
# 786
Out of 4,905 analysts
75
Total ratings
45.76%
Success rate
8.16%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $225.58 | +6.39% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.71 | -10.51% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.49 | -19.89% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $31.16 | +92.55% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $190.05 | +65.75% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $414.75 | +63.95% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $116.25 | +46.24% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $4.27 | +17.10% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $2.02 | +444.55% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $24.90 | +52.61% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $7.19 | +136.44% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.36 | +83.82% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $52.02 | +67.24% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $210.89 | +84.93% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $6.24 | +188.46% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.82 | +112.77% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $20.83 | +39.22% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $154.48 | +144.04% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $225.58
Upside: +6.39%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.71
Upside: -10.51%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.49
Upside: -19.89%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $31.16
Upside: +92.55%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $190.05
Upside: +65.75%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $414.75
Upside: +63.95%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $116.25
Upside: +46.24%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.27
Upside: +17.10%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.02
Upside: +444.55%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $24.90
Upside: +52.61%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $7.19
Upside: +136.44%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.36
Upside: +83.82%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $52.02
Upside: +67.24%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $210.89
Upside: +84.93%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $6.24
Upside: +188.46%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.82
Upside: +112.77%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $20.83
Upside: +39.22%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $154.48
Upside: +144.04%